Literature DB >> 17279417

Transforming growth factor-beta downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma.

Cheryn Song1, Sun-Young Jun, Jun-Hyuk Hong, Hanjong Ahn.   

Abstract

PURPOSE: We investigated signal transducer and activator of transcription-5 (STAT5) activation status in renal cell carcinoma (RCC) and the role of transforming growth factor-beta (TGF-beta) in the process.
METHODS: Twenty normal and RCC tissues were obtained from radical nephrectomy specimens for the assessment of expressions of phosphorylated STAT5 (p-STAT5) and TGF-beta1 (Western blot) and for localization and assessment of their relationship (immunohistochemical and immunofluorescence stains). By using four RCC cell lines and four primary cultured cells, the effect of TGF-beta1 and/or interleukin-2 (IL-2) on the expressions of p-STAT5 were analyzed.
RESULTS: In RCC samples, expression of p-STAT5 was significantly reduced while expression of TGF-beta was enhanced compared with normal kidney tissues (P < 0.001 and P = 0.003, respectively). P-STAT5 was observed almost exclusively in the nuclei of normal kidney tissues while TGF-beta was identified in the cytoplasm of cells of both tissues reflecting the Western results. In both RCC cell lines and cells from primary cultures, treatment with TGF-beta or antibody did not significantly alter STAT5 activation. However, TGF-beta significantly suppressed IL-2-induced STAT5 activation, whereas anti-TGF-beta antibodies enhanced IL-2-induced STAT5 further.
CONCLUSIONS: STAT5 activation is suppressed in RCC compared with normal renal parenchyma. It may be attributed to the RCC-derived TGF-beta which also interferes with IL-2-induced STAT5 pathway activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17279417     DOI: 10.1007/s00432-007-0192-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  16 in total

1.  Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts.

Authors:  K U Birkenkamp; M Geugien; H H Lemmink; W Kruijer; E Vellenga
Journal:  Leukemia       Date:  2001-12       Impact factor: 11.528

2.  Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma.

Authors:  U Ramp; K Jaquet; P Reinecke; T Nitsch; H E Gabbert; C D Gerharz
Journal:  Lab Invest       Date:  1997-05       Impact factor: 5.662

3.  Elevated plasma TGF-beta1 in renal diseases: cause or consequence?

Authors:  U Junker; C C Haufe; K Nuske; K Rebstock; T Steiner; H Wunderlich; K Junker; D Reinhold
Journal:  Cytokine       Date:  2000-07       Impact factor: 3.861

4.  TGF-beta does not inhibit IL-12- and IL-2-induced activation of Janus kinases and STATs.

Authors:  C Sudarshan; J Galon; Y Zhou; J J O'Shea
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

5.  Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins.

Authors:  S Takemoto; J C Mulloy; A Cereseto; T S Migone; B K Patel; M Matsuoka; K Yamaguchi; K Takatsuki; S Kamihira; J D White; W J Leonard; T Waldmann; G Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

6.  Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma.

Authors:  Akira Miyajima; Tomohiko Asano; Kaori Seta; Takako Asano; Narihiko Kakoi; Masamichi Hayakawa
Journal:  Urology       Date:  2003-05       Impact factor: 2.649

7.  Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade.

Authors:  Hongzhen Li; Tommi J Ahonen; Kalle Alanen; Jianwu Xie; Matthew J LeBaron; Thomas G Pretlow; Erica L Ealley; Ying Zhang; Martti Nurmi; Baljit Singh; Paula M Martikainen; Marja T Nevalainen
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

Review 8.  Signal transducer and activator of transcription 5 (STAT5).

Authors:  Miranda Buitenhuis; Paul J Coffer; Leo Koenderman
Journal:  Int J Biochem Cell Biol       Date:  2004-11       Impact factor: 5.085

9.  Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue.

Authors:  Dionisios Mitropoulos; Aspasia Kiroudi; Evangelia Christelli; Efraim Serafetinidis; Anastasios Zervas; Ioannis Anastasiou; Constantinos Dimopoulos
Journal:  Urol Res       Date:  2004-09-07

10.  Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis.

Authors:  J-R Hsiao; Y-T Jin; S-T Tsai; A-L Shiau; C-L Wu; W-C Su
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

View more
  3 in total

1.  Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors.

Authors:  Sahyun Pak; Wansuk Kim; Yunlim Kim; Cheryn Song; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-10       Impact factor: 4.553

2.  Activation of Stat3 in renal tumors.

Authors:  Charles Guo; Guanyu Yang; Kyle Khun; Xiantian Kong; David Levy; Peng Lee; Jonathan Melamed
Journal:  Am J Transl Res       Date:  2009-02-28       Impact factor: 4.060

3.  In vivo identification of novel STAT5 target genes.

Authors:  Beth Basham; Manjiri Sathe; Jeffrey Grein; Terrill McClanahan; Annalisa D'Andrea; Emma Lees; Anne Rascle
Journal:  Nucleic Acids Res       Date:  2008-05-20       Impact factor: 16.971

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.